Artigo de periodico

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study (2018)

• Authors:
  • Robak, Tadeusz
  • Jin, Jie
  • Pylypenko, Halyna
  • Verhoef, Gregor
  • Siritanaratkul, Noppadol
  • Drach, Johannes
  • Raderer, Markus
  • Mayer, Jiri
  • Pereira, Juliana
  • Tumyan, Gayane
• Autor USP: PEREIRA, JULIANA - FM
• Unidade: FM
• DOI: 10.1016/S1470-2045(18)30685-5
• Subjects: LINFOMA; IMUNOTERAPIA; ESTUDOS RANDOMIZADOS; ANTINEOPLÁSICOS
• Agências de fomento:
  • Janssen Research Development
• Language: Inglês
• Imprenta:
  • Publisher place: New York
  • Date published: 2018
• Source:
  • Título do periódico: Lancet oncology
  • ISSN: 1470-2045
  • Volume/Número/Paginação/Ano: v. 19, n. 11, p. 1449-1458, 2018

Informações sobre o DOI: 10.1016/S1470-2045(18)30685-5 (Fonte: oaDOI API)
• Este periódico é de assinatura
• Este artigo é de acesso aberto
• URL de acesso aberto
• Cor do Acesso Aberto: green
• Licença: other-oa

---

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  ROBAK, Tadeusz et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet oncology, v. 19, n. 11, p. 1449-1458, 2018Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(18)30685-5. Acesso em: 19 abr. 2024.

• APA

  Robak, T., Jin, J., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Drach, J., et al. (2018). Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet oncology, 19( 11), 1449-1458. doi:10.1016/S1470-2045(18)30685-5

• NLM

  Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study [Internet]. Lancet oncology. 2018 ; 19( 11): 1449-1458.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1016/S1470-2045(18)30685-5

• Vancouver

  Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study [Internet]. Lancet oncology. 2018 ; 19( 11): 1449-1458.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1016/S1470-2045(18)30685-5

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• CD4+ lymphocytes in asymptomatic HTLV-1 carriers present cell cycle arrest in GO/G1 phase
• Expression of CysLTR1 and 2 in Maturating Lymphocytes of Hyperplasic Tonsils Compared to Peripheral Cells in Children
• Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome
• Time-to-treatment of diffuse large B-cell lymphoma in São Paulo
• Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study
• Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances
• Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma
• Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings
• 18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era
• Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*)